Abstract
Clever-1 expression in macrophages contributes to impaired antigen presentation and suppression of anti-tumor immunity. This first-in-human trial was designed to investigate the safety and tolerability of Clever-1 blockade in patients with treatment-refractory solid tumors and to assess preliminary anti- tumor efficacy, pharmacodynamics, and immunologic correlates. Bexmarilimab was well tolerated with no observed dose limiting toxicities in part I (n=30) and no additional safety signals in part II (n=108). Disease control (DC) rates of 25-40% were observed in cutaneous melanoma, gastric, hepatocellular, estrogen receptor positive breast, and biliary tract cancers, which associated with improved survival in a landmark analysis. High pre-treatment intra-tumoral Clever-1 staining and low circulating TNFα correlated with DC. Digital spatial profiling of DC and non-DC tumors with next generation sequencing showed bexmarilimab-induced macrophage activation and robust stimulation of IFNγ and T-cell receptor signaling selectively in DC patients. These data suggest that bexmarilimab therapy is well-tolerated and show that macrophage targeting can promote tumor control in late stage cancer.
Highlights
Targeting Clever-1 with bexmarilimab is well tolerated
Disease control in late stage cancer can be achieved with bexmarilimab monotherapy
Low baseline immune activation associates with bexmarilimab benefit
Bexmarilimab converts intratumoral macrophages to support adaptive immune responses
Competing Interest Statement
LV declares consulting fees from Adaptherapy; Stock or stock options for Resolved. MdM declares payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Janssen and MSD AP declares payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Incyte and Roche; Support for attending meetings and/or travel from Gilead; Participation on a Data Safety Monitoring Board or Advisory Board for Incyte, Novartis, Gilead, and BeiGen. DB declares consulting fees from Merck AG, Pfizer, Bayer, Cantargia AB, Faron Pharmaceuticals, and Servier. TS declares payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from BMS; Participation on a Data Safety Monitoring Board or Advisory Board for Faron Pharmaceuticals, Merck, and Novartis; Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid for Finnish Oncology Society. SI declares grants or contracts from any entity from Roche and AstraZeneca; Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from BMS, Roche, Astra Zeneca, Takeda, Novartis, MSD, Pierre Fabre, Boehringer-Ingelheim. SS declares consulting fees from Faron Pharmaceuticals, Participation on a Data Safety Monitoring Board or Advisory Board for Faron Pharmaceuticals. YTM declares consulting fees from Eisai, Roche, AstraZeneca, Ipsen; Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events for Bayer, Boston Scientific; Participation on a Data Safety Monitoring Board or Advisory Board for Faron Pharmaceuticals. DG declares consulting fees from Clinigen and McCann Health; Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Cancer Drug Development Fund and Pfizer. SPA declares payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Bayer, BMS, ASCO, and Exelixis; Participation on a Data Safety Monitoring Board or Advisory Board for AstraZeneca, Seagen, and QED Therapeutics/Helsinn; Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid for Board-Support New India. PJ declares Participation on a Data Safety Monitoring Board or Advisory Board for Faron Pharmaceuticals. CY declares consulting fees from Faron Pharmaceuticals; Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Bayer. JM declares all support for the present manuscript from Faron Pharmaceuticals (employment); Patents planned, issued or pending for Faron Pharmaceuticals; Participation on a Data Safety Monitoring Board or Advisory Board for Faron Pharmaceuticals; Stock or stock options for Faron Pharmaceuticals. MKK declares all support for the present manuscript from Faron Pharmaceuticals (employment); Patents planned, issued or pending for Faron Pharmaceuticals; Stock or stock options for Faron Pharmaceuticals. JJ declares all support for the present manuscript from Faron Pharmaceuticals (employment); Grants or contracts from any entity from European Innovation Council; Stock or stock options for Faron Pharmaceuticals. JPK declares all support for the present manuscript from Faron Pharmaceuticals; Consulting fees from MSD, BMS, Roche, Pfizer, and AstraZeneca; Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from MSD, BMS, Roche, AstraZeneca, and Sanofi; Payment for expert testimony from Sanofi; Support for attending meetings and/or travel from BMS; Participation on a Data Safety Monitoring Board or Advisory Board for Faron Pharmaceuticals; Stock or stock options from Faron Pharmaceuticals. AM declares payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Janssen, Chugai, Novartis, and Bayer; Support for attending meetings and/or travel from Amgen; Participation on a Data Safety Monitoring Board or Advisory Board for Janssen, Takeda, Genmab, Merck, and Faron Pharmaceuticals. MH declares all support for the present manuscript from Faron Pharmaceuticals; Consulting fees from Faron Pharmaceuticals; Stock or stock options from Faron Pharmaceuticals PB declares consulting fees from Faron Pharmaceuticals, Herantis Pharma, MSD Oncology, Ipsen, Oncorena, TILT biotherapeutics; Participation on a Data Safety Monitoring Board or Advisory Board for Faron Pharmaceuticals, TILT biotherapeutics and Oncorena; Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid for Terveystalo (employment); Stock or stock options for Terveystalo, TILT biotherapeutics; Other financial or non-financial interests for Faron pharmaceuticals, stock ownership (spouse)
Clinical Trial
NCT03733990
Funding Statement
This study was funded by Faron Pharmaceuticals (Turku, Finland), European Unions Horizon 2020 research and innovation program (ID: 960914), the Academy of Finland, Business Finland, Cancer Foundations, the Sigrid Juselius foundation, Orion Research Foundation and the Paulo Foundation.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Local institutional ethical committees of Oulu University Hospital, Helsinki University Hospital, Tampere University Hospital, Turku University Hospital, University Hospitals Birmingham, Institut Gustave Roussy, Royal Marsden Hospital, Erasmus Medical Center, The Christie NHS Foundation Trust and Mays Cancer Center gave ethical approval for this work. The study was approved by national medicinal agencies (MATINS; NCT03733990, EudraCT 2018-002732-24).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors
